Search
ChatPaper
AI Writing
analysis
Analysis
编组
Open Data
more
More
RankingsMust ReadingJournal&ConferenceAI TRAI HistoryMaster Reading TreeXiaomai's Star TalentsTrajectoryTalentNDI TrackerOpenAI sign Language
VIPCreated with Sketch.

c-Met/ErbB3/PI3K信号通路在肺癌EGFRTKI获得性耐药中的研究进展

贾文韫,李宝兰,岳文涛

CANCER RESEARCH ON PREVENTION AND TREATMENT（2011）

Cited 1|Views3
No score
Abstract
0 引言 目前小分子酪氨酸激酶抑制剂(tyrosine kinase inhibitor,TKI)包括吉非替尼(Gefitinib)和厄洛替尼(Erlotinb),作为二线药物在非小细胞肺癌的临床治疗中取得了明显疗效.但在临床使用中,EGFR-TKI敏感病人在用药6～8月后部分出现了疾病进展即获得性耐药,获得性耐药的发生使小分子酪氨酸激酶抑制剂的应用受到了极大的限制[1].
More
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined